Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 7:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 814 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Liver Disease Clear all
Completed Phase 1 Interventional

Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C

NCT00718172
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Liver Biopsy, Peginterferon & Ribavirin for Hepatitis C, Pre-treatment Ribavirin
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 2 Interventional Results available

Once-Daily Oral Avatrombopag Tablets Used in Subjects With Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures

NCT00914927
View directory record Official record
Conditions
Thrombocytopenia Related to Chronic Liver Disease
Interventions
Avatrombopag, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Not applicable Interventional Results available

Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2)

NCT04283994
View directory record Official record
Conditions
Dementia, Chronic Disease, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Lung Diseases, Interstitial, Peripheral Vascular Disease, Diabetes With End Organ Injury
Interventions
Survey-based Patient/Clinician Jumpstart, EHR-based Clinician Jumpstart
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

NCT02486406
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin, Ombitasvir mini tablet, Paritaprevir mini tablet, Ritonavir mini tablet, Dasabuvir mini tablet, Ribavirin solution
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 2 Interventional

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

NCT00277238
View directory record Official record
Conditions
Hepatitis, Chronic Active
Interventions
CPG10101, Control
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 1Phase 2 Interventional

A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C

NCT00246363
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Silymarin, Placebo
Drug
Lead sponsor
Henry Sacks
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Sep 21, 2026, 7:48 AM EDT
Recruiting No phase listed Observational

MRI Based Biomarkers in Pediatric Autoimmune Liver Disease

NCT03175471
View directory record Official record
Conditions
Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 23 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis

NCT00973817
View directory record Official record
Conditions
Acute On Chronic Hepatitis
Interventions
ELAD plus standard of care treatment, Standard of care
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Sep 21, 2026, 7:48 AM EDT
Completed No phase listed Observational

Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT

NCT01825213
View directory record Official record
Conditions
Chronic Liver Disease, HepatoCellular Carcinoma, Liver Fibrosis
Interventions
Multispectral CT of the liver
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 4 Interventional Results available

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

NCT04575896
View directory record Official record
Conditions
End Stage Renal Disease, Hepatitis C
Interventions
Glecaprevir/pibrentasvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00978497
View directory record Official record
Conditions
HCV Infection
Interventions
placebo, ANA598, Peginterferon, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • San Clemente, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

NCT01817985
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
GS-5816
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Sep 21, 2026, 7:48 AM EDT
Completed No phase listed Observational

Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing

NCT02068963
View directory record Official record
Conditions
Hepatitis C
Interventions
Not listed
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
33
States / cities
North Little Rock, Arkansas • Bakersfield, California • Rialto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Not applicable Interventional Results available

Covered Metallic Stents for First-Line Treatment of Benign Bile Duct Strictures

NCT01221311
View directory record Official record
Conditions
Common Bile Duct Stricture
Interventions
Fully covered Metallic Stent, Plastic Stent
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Chicago, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 21, 2026, 7:48 AM EDT
Terminated Not applicable Interventional Results available

Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

NCT02503735
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Disease
Interventions
Sofosbuvir/Ledipasvir FDC
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study

NCT03987503
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 1 Interventional

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

NCT04454424
View directory record Official record
Conditions
Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions
BAY1817080, Midazolam
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 4 Interventional Results available

Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3

NCT00056862
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 1 Interventional

Open-Label Hepatic Impairment Study

NCT01497327
View directory record Official record
Conditions
Hepatitis C
Interventions
PSI-352938, PSI-7977
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 21, 2026, 7:48 AM EDT
Terminated No phase listed Observational

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

NCT03692897
View directory record Official record
Conditions
Hepatitis B, Hepatitis, Liver Diseases
Interventions
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Other
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 21, 2026, 7:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

NCT06537414
View directory record Official record
Conditions
Chronic Hepatitis B Virus Infection, Hepatitis B
Interventions
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects

NCT02095587
View directory record Official record
Conditions
Hepatic Impairment
Interventions
IPI-145
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection

NCT01492426
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Telaprevir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 21, 2026, 7:48 AM EDT
Completed Phase 3 Interventional

Trial of Peg-interferon Plus Epoetin-alfa for Treatment of Chronic Hepatitis C Virus Infection

NCT00248339
View directory record Official record
Conditions
Hepatitis C
Interventions
Peginterferon-alpha-2b (PEG-Intron), Ribavirin, Epoetin-alpha (Procrit)
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Sep 21, 2026, 7:48 AM EDT